Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Esophageal Neoplasms 10Carcinoma, Hepatocellular 10Rectal Neoplasms 9Colorectal Neoplasms 8Stomach Neoplasms 7Pancreatic Neoplasms 7Colonic Neoplasms 7Lung Neoplasms 6Breast Neoplasms 6Urinary Bladder Neoplasms 4Cholangiocarcinoma 4Carcinoma, Transitional Cell 4Salivary Gland Neoplasms 3Ovarian Neoplasms 3Neuroendocrine Tumors 3Liver Neoplasms 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Anus Neoplasms 3Adenocarcinoma Of Esophagus 3Uterine Cervical Neoplasms 2Tongue Neoplasms 2Thyroid Neoplasms 2Testicular Neoplasms 2Sarcoma 2Oropharyngeal Neoplasms 2Nasopharyngeal Neoplasms 2Mouth Neoplasms 2Laryngeal Neoplasms 2

Interventions

lutetium Lu 177 dotatate 8lanreotide 4copper dotatate CU-64 4Octreotide 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4pasireotide 3Magnetic Resonance Spectroscopy 3Lutetium-177 3Lutetium 3gallium Ga 68 dotatate 2amino-acid, glucose, and electrolyte solution 2Temozolomide 2Nivolumab 2Irinotecan 2Ga(III)-DOTATOC 2Everolimus 2Etoposide 2Carboplatin 2zimberelimab 1regorafenib 1pembrolizumab 1irinotecan sucrosofate 1folfirinox 1famitinib 1cabozantinib 1arginyllysine 1abemaciclib 1X-Rays 1Sunitinib 1Somatostatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastro-enteropancreatic neuroendocrine tumor × Fluorodeoxyglucose F18 × Gastrointestinal × Clear all
NCT05709171 2023-11-22

Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms

Rigshospitalet, Denmark

Phase 2 Unknown
200 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡